MUMBAI (Reuters) - Cipla Ltd, India's fourth-largest drugmaker by sales, said on Friday it has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million to get access to a wide range of products.
The companies to be acquired, InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc, had combined sales of $225 million in the last twelve months to June 2015, Cipla said in a statement.
(Reporting by Zeba Siddiqui in Mumbai)